The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer

Effective drugs are needed for lung cancer, as this disease remains the leading cause of cancer-related deaths. Rexinoids are promising drug candidates for cancer therapy because of their ability to modulate genes involved in inflammation, cell proliferation or differentiation, and apoptosis through...

Descripción completa

Detalles Bibliográficos
Autores principales: Moerland, Jessica A., Zhang, Di, Reich, Lyndsey A., Carapellucci, Sarah, Lockwood, Beth, Leal, Ana S., Krieger-Burke, Teresa, Aleiwi, Bilal, Ellsworth, Edmund, Liby, Karen T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746742/
https://www.ncbi.nlm.nih.gov/pubmed/33335263
http://dx.doi.org/10.1038/s41598-020-79260-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746742/
https://www.ncbi.nlm.nih.gov/pubmed/33335263
http://dx.doi.org/10.1038/s41598-020-79260-8

Ejemplares similares